ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … July 21, 2020
ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. October 15, 2019
ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … July 13, 2020
ProQR Appoints Theresa Heggie as Chief Commercial Officer Press release Senior leader with extensive global rare disease commercialization experience Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 October 04, 2021
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … March 07, 2022
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … December 30, 2021
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … May 04, 2021
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Press release … amaurosis 10, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA … July 29, 2019
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … January 04, 2022
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly Press release Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer® RNA edit September 08, 2021